UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 32,653 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 23.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 170,100 shares of the company's stock after buying an additional 32,653 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.20% of Syndax Pharmaceuticals worth $2,249,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in SNDX. Soleus Capital Management L.P. boosted its holdings in shares of Syndax Pharmaceuticals by 128.4% in the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock worth $32,944,000 after buying an additional 1,401,016 shares during the period. Octagon Capital Advisors LP acquired a new position in shares of Syndax Pharmaceuticals in the fourth quarter worth about $11,951,000. Renaissance Technologies LLC acquired a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth approximately $9,002,000. Trexquant Investment LP grew its position in Syndax Pharmaceuticals by 1,309.7% during the fourth quarter. Trexquant Investment LP now owns 471,292 shares of the company's stock valued at $6,230,000 after purchasing an additional 437,859 shares in the last quarter. Finally, Altium Capital Management LLC purchased a new position in Syndax Pharmaceuticals during the fourth quarter valued at approximately $4,891,000.

Wall Street Analyst Weigh In

A number of research analysts recently commented on SNDX shares. JPMorgan Chase & Co. boosted their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research report on Thursday, March 20th. Guggenheim reaffirmed a "buy" rating and set a $32.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Citigroup lowered their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Scotiabank boosted their price objective on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $35.91.

Syndax Pharmaceuticals Trading Up 2.6%

NASDAQ SNDX traded up $0.29 during trading on Friday, reaching $11.45. The company's stock had a trading volume of 1,341,845 shares, compared to its average volume of 1,794,115. The stock has a market capitalization of $985.24 million, a PE ratio of -3.15 and a beta of 0.74. The business has a 50-day moving average price of $11.32 and a 200-day moving average price of $13.26. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.06. The business had revenue of $20.04 million during the quarter, compared to analyst estimates of $15.88 million. During the same quarter last year, the firm earned ($0.85) earnings per share. Syndax Pharmaceuticals's revenue was up 1900.0% compared to the same quarter last year. As a group, analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).